|
NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN
|
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2014
|
||
| Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
| Nature Of Business Organization and Going Concern Disclosure [Text Block] |
1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN
The Company is a biopharmaceutical company developing compounds for the treatment and imaging of cancer. Prior to February 11, 2014, the name of the Company was Novelos Therapeutics, Inc. (“Novelos”). On April 8, 2011, Novelos entered into a business combination (the “Acquisition”) with Cellectar, Inc., a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers. References in these financial statements and notes to “Cellectar, Inc.” relate to the activities and financial information of Cellectar, Inc. prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “Cellectar Bio” or “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.
The Company’s headquarters are located in Madison, Wisconsin.
The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.
The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $59,111,670 (restated) at December 31, 2014. During the year ended December 31, 2014, the Company generated a net loss of $8,052,102 (restated) and the Company expects that it will continue to generate operating losses for the foreseeable future. On February 6, 2014, we completed a private placement of convertible debentures and warrants for gross proceeds of $4,000,000 (the “February 2014 Private Placement”). On August 20, 2014, we completed an underwritten public offering of common shares and warrants to purchase common shares for gross proceeds of $13,475,832; additionally, all holders of the debentures and warrants issued in the February 2014 Private Placement elected to participate in the August 2014 Underwritten Offering, resulting in the extinguishment of the February 2014 Private Placement debentures and warrants in exchange for 1,109,960 shares of the Company’s common stock and warrants to purchase 1,109,690 shares of common stock at $4.68 per share (see Note 8). The Company believes that its cash balance at December 31, 2014 is adequate to fund operations at budgeted levels through September 2015. The Company’s ability to execute its operating plan beyond September 2015 depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
|